“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: Kazia Therapeutics
Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.
Kazia Therapeutics — 9 videos in collection
In the second part of this three-episode Edison TV series, Kazia Therapeutics (KZIA), dives deeper into paxalisib for additional indications beyond glioblastoma. These indications include DIPG, a highly aggressive childhood brain cancer, primary CNS lymphoma, and brain metastases.
John Friend, CMO, discusses ongoing investigator-initiated trials and collaborations. James Garner, CEO, addresses commercialisation plans.
Get access to the very latest content matched to your personal investment style.
